Trial Outcomes & Findings for EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) (NCT NCT05742841)
NCT ID: NCT05742841
Last Updated: 2024-05-21
Results Overview
A lipid panel is a common blood test that healthcare providers use to monitor and screen for risk of cardiovascular disease. The panel includes three measurements of your cholesterol levels and a measurement of your triglycerides.
Recruitment status
COMPLETED
Study phase
PHASE4
Target enrollment
22 participants
Primary outcome timeframe
Baseline and Day 30
Results posted on
2024-05-21
Participant Flow
Participant milestones
| Measure |
EMERALD Protocol
1\) ordering a lipid panel during the index ED encounter and 30-days (+/- 5 business days) after ED discharge, 2) completion of the Pooled Cohort Equations by the patient's ED provider at the index visit, and 3) starting medical therapy (moderate- or high-intensity statin/ rosuvastatin) in the ED
moderate- or high-intensity statin/ rosuvastatin: moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
|
|---|---|
|
Overall Study
STARTED
|
22
|
|
Overall Study
COMPLETED
|
20
|
|
Overall Study
NOT COMPLETED
|
2
|
Reasons for withdrawal
| Measure |
EMERALD Protocol
1\) ordering a lipid panel during the index ED encounter and 30-days (+/- 5 business days) after ED discharge, 2) completion of the Pooled Cohort Equations by the patient's ED provider at the index visit, and 3) starting medical therapy (moderate- or high-intensity statin/ rosuvastatin) in the ED
moderate- or high-intensity statin/ rosuvastatin: moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
|
|---|---|
|
Overall Study
Withdrawal by Subject
|
1
|
|
Overall Study
Lost to Follow-up
|
1
|
Baseline Characteristics
EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)
Baseline characteristics by cohort
| Measure |
EMERALD Protocol
n=20 Participants
1\) ordering a lipid panel during the index ED encounter and 30-days (+/- 5 business days) after ED discharge, 2) completion of the Pooled Cohort Equations by the patient's ED provider at the index visit, and 3) starting medical therapy (moderate- or high-intensity statin/ rosuvastatin) in the ED
moderate- or high-intensity statin/ rosuvastatin: moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=39 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
19 Participants
n=39 Participants
|
|
Age, Categorical
>=65 years
|
1 Participants
n=39 Participants
|
|
Age, Continuous
|
53.5 years
n=39 Participants
|
|
Sex: Female, Male
Female
|
13 Participants
n=39 Participants
|
|
Sex: Female, Male
Male
|
7 Participants
n=39 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=39 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=39 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=39 Participants
|
|
Race (NIH/OMB)
Black or African American
|
14 Participants
n=39 Participants
|
|
Race (NIH/OMB)
White
|
6 Participants
n=39 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=39 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=39 Participants
|
|
Region of Enrollment
United States
|
20 Participants
n=39 Participants
|
PRIMARY outcome
Timeframe: Baseline and Day 30Population: only participants that qualified for study drug were analyzed - 16, not all 20 Participants
A lipid panel is a common blood test that healthcare providers use to monitor and screen for risk of cardiovascular disease. The panel includes three measurements of your cholesterol levels and a measurement of your triglycerides.
Outcome measures
| Measure |
EMERALD Protocol
n=16 Participants
1\) ordering a lipid panel during the index ED encounter and 30-days (+/- 5 business days) after ED discharge, 2) completion of the Pooled Cohort Equations by the patient's ED provider at the index visit, and 3) starting medical therapy (moderate- or high-intensity statin/ rosuvastatin) in the ED
moderate- or high-intensity statin/ rosuvastatin: moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
|
|---|---|
|
Low-density Lipoprotein Cholesterol (LDL-C) Levels at Baseline and Day 30
Baseline LDL-C
|
110 mg/dL
Interval 89.5 to 144.5
|
|
Low-density Lipoprotein Cholesterol (LDL-C) Levels at Baseline and Day 30
Day 30 LDL-C
|
84.0 mg/dL
Interval 60.0 to 111.0
|
Adverse Events
EMERALD Protocol
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place